Enliven Therapeutics Inc (NASDAQ:ELVN) price on current trading day, rose 8.75% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $21.38.
A look at the stock’s price movement, the level at last check in today’s session was $19.66, moving within a range at $18.53 and $22.66. The beta value (5-Year monthly) was 0.951. Turning to its 52-week performance, $30.03 and $13.30 were the 52-week high and 52-week low respectively. Overall, ELVN moved 7.49% over the past month.
Enliven Therapeutics Inc’s market cap currently stands at around $1.05 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-13.
ELVN’s current price about 13.47% and 16.00% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 58.67, while 7-day volatility ratio is 6.87% and 6.02% in the 30-day chart. Further, Enliven Therapeutics Inc (ELVN) has a beta value of 0.81, and an average true range (ATR) of 1.66. Analysts have given the company’s stock an average 52-week price target of $39, forecast between a low of $39 and high of $39. Looking at the price targets, the low is -82.41% off recent price level in today’s trading while to achieve the yearly target high, it has to move -82.41%. Nonetheless, investors will most likely welcome a -82.41% jump to $39 which is the analysts’ median price.
If we refocus on Enliven Therapeutics Inc (NASDAQ:ELVN), historical trading data shows that trading volumes averaged 0.47 over the past 10 days and 347.66K over the past 3 months. The company’s latest data on shares outstanding shows there are 49.04 million shares.
The 34.33% of Enliven Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 73.72% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.5 million on 2025-05-30, giving us a short ratio of 18.82. The data shows that as of 2025-05-30 short interest in Enliven Therapeutics Inc (ELVN) stood at 2070.0 of shares outstanding, with shares short falling to 6.96 million registered in 2025-04-30. Current price change has pushed the stock -4.98% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ELVN stock continues to rise going into the next quarter.
